A detailed history of Vanguard Group Inc transactions in Maxcyte, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,775,268 shares of MXCT stock, worth $20.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,775,268
Previous 5,645,122 2.31%
Holding current value
$20.5 Million
Previous $22.1 Million 1.52%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.68 - $5.06 $478,937 - $658,538
130,146 Added 2.31%
5,775,268 $22.5 Million
Q2 2024

Aug 13, 2024

BUY
$3.63 - $5.0 $1.08 Million - $1.49 Million
298,010 Added 5.57%
5,645,122 $22.1 Million
Q1 2024

May 10, 2024

BUY
$3.94 - $5.38 $256,115 - $349,721
65,004 Added 1.23%
5,347,112 $22.4 Million
Q4 2023

Feb 14, 2024

BUY
$2.6 - $5.24 $632,478 - $1.27 Million
243,261 Added 4.83%
5,282,108 $24.8 Million
Q3 2023

Nov 14, 2023

BUY
$3.02 - $5.1 $205,109 - $346,376
67,917 Added 1.37%
5,038,847 $15.7 Million
Q2 2023

Aug 14, 2023

BUY
$3.69 - $5.35 $304,266 - $441,144
82,457 Added 1.69%
4,970,930 $22.8 Million
Q1 2023

May 15, 2023

BUY
$4.03 - $5.89 $162,634 - $237,696
40,356 Added 0.83%
4,888,473 $24.2 Million
Q4 2022

Feb 10, 2023

BUY
$4.92 - $7.4 $899,361 - $1.35 Million
182,797 Added 3.92%
4,848,117 $26.5 Million
Q3 2022

Nov 14, 2022

BUY
$4.52 - $6.51 $5.74 Million - $8.27 Million
1,269,810 Added 37.4%
4,665,320 $30.3 Million
Q2 2022

Aug 12, 2022

BUY
$3.59 - $6.81 $398,181 - $755,324
110,914 Added 3.38%
3,395,510 $16.1 Million
Q1 2022

May 13, 2022

BUY
$5.26 - $10.84 $667,525 - $1.38 Million
126,906 Added 4.02%
3,284,596 $23 Million
Q4 2021

Feb 14, 2022

BUY
$8.87 - $12.94 $3.58 Million - $5.22 Million
403,373 Added 14.65%
3,157,690 $32.2 Million
Q3 2021

Nov 12, 2021

BUY
$12.21 - $17.2 $33.6 Million - $47.4 Million
2,754,317 New
2,754,317 $33.6 Million

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $361M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.